[Skip to Navigation]
October 1986

Failure of Human Growth Hormone to Benefit Ehlers-Danlos Syndrome

Author Affiliations

Department of Dermatology; Department of Surgery University of California; Laboratory of Growth and Development Children's Hospital of San Francisco San Francisco, CA 94119

Arch Dermatol. 1986;122(10):1099-1100. doi:10.1001/archderm.1986.01660220013005

To the Editor.—  Prudden et al1 described increased wound tensile strength in rats treated with bovine growth hormone. Aloia and Grover2 described improvement of the abnormally thin skin of five patients with osteoporosis treated with human growth hormone (hGH). The collagen bundles and elastic tissue fibers became hyperplastic and more horizontally oriented. There was proliferation of blood vessels, and increased numbers of mast cells and fibrocytes. Reports differ as to whether structural abnormalities do3 or do not4 occur in types I and II Ehlers-Danlos (ED) syndrome. In view of the lack of effective therapy for ED, a trial of hGH seemed reasonable.Hydroxyproline accumulation in subcutaneous wounds was determined by the use of polytetrafluoroethylene (PTFE, Gore-Tex) tubing implanted subcutaneously in the outer arm, and removed at five and seven days,5 and is expressed as micrograms per centimeter of tubing. The seven-day value is regarded

Add or change institution